Prescryptive Health, a healthcare technology company empowering consumers by improving the way healthcare is delivered, announced a partnership with the Diabetes Research Institute Foundation (DRIF). In the innovative partnership, both organizations will work with employer groups to donate the cost savings from Prescryptive’s pharmacy benefits plan to DRIF. Typically, Prescryptive’s pharmacy benefits clients see up to 40% savings from lower drug prices, smarter plan design, and increased employee engagement.
“At Prescryptive, we’re challenging the way pharmacy benefits managers make money by bringing transparency to drug pricing,” said Chris Blackley, Prescryptive Health CEO. “This commitment lowers healthcare costs and opens up an opportunity to further invest in health outcomes. We are proud to partner with DRIF and support their groundbreaking work by turning those savings into funds for research and patient education.”
“This is a natural partnership for us, because of Prescryptive’s commitment to transparency and lower drug prices,” said Sean Kramer, DRIF CEO. “The company is setting a precedent for how diabetes patients like me get their prescription medications and pay less for them. We’re proud to create this partnership to further our research toward a cure through seamless corporate giving that’s connected to employee health.”
One in 10 Americans has diabetes, and one in three—88 million adults—has prediabetes. The goal of the foundation, one of the world’s most respected diabetes organizations, is to support the Diabetes Research Institute in finding a cure.
Prescryptive Health was founded in 2017 with a focus on lowering costs for prescription drugs through a transparent pharmacy benefits model. Early on, the company drove lower insulin costs by contracting directly with manufacturers and passing 100% of the savings on to employers and patients. The partnership with DRIF grew out of this work.
